LIVERFASt Demonstrates the Feasibility of a Screening Program for MASLD easlfibronostg on June 25, 2026 Category: Publications Tag: LIVERFASt, MASLD, NAFLD, Screening Post navigation Previous: Previous post: Fibronostics Achieves SOC 2 Compliance CertificationNext: Next post: Application of LIVERFASt to predict steatosis in Chronic Hepatitis B patients with metabolic syndrome
